Merck To Settle Charges Vioxx Was Illegally Promoted

Pharmaceutical company Merck has agreed to pay nearly $1 billion to settle charges that it illegally marketed its painkiller Vioxx. The drug was taken off the market in 2004 after questions were raised about its safety.

Copyright © 2011 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

LINDA WERTHEIMER, HOST:

The pharmaceutical company Merck has agreed to pay nearly a billion dollars to settle charges that it illegally marketed its painkiller, Vioxx. The drug was taken off the market in 2004 after questions were raised about its safety. NPR's Jim Zarroli reports.

JIM ZARROLI, BYLINE: Merck agreed to plead guilty to a single charge of violating food and drug regulations. It will pay a criminal fine worth $321 million. The company also agreed to a civil settlement of $628 million. It has already paid nearly $5 billion to settle private lawsuits about the drug. Vioxx was approved for sale in 1999, but it was taken off the market after evidence emerged that it doubled the risk of heart attacks.

The government says Merck's sales representatives promoted the drug as a treatment for rheumatoid arthritis, even though it hadn't been approved for it. The company continued to do so even after it was warned by the Food and Drug Administration to stop. The government also says Merck lied to state Medicaid agencies about the safety of Vioxx. The company confirmed the settlement in a statement. Merck also said that the settlement did not mean upper management knew about any of the illegal conduct the government accuses the company of. Jim Zarroli, NPR News, New York.

Copyright © 2011 NPR. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to NPR. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.